Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Heartbeam Inc. Warrant (BEATW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: BEATW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.64% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.29 - 0.95 | Updated Date 02/24/2025 |
52 Weeks Range 0.29 - 0.95 | Updated Date 02/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.31% | Return on Equity (TTM) -164.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5185854 |
Shares Outstanding - | Shares Floating 5185854 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Heartbeam Inc. Warrant
Company Overview
History and Background
Heartbeam, Inc. focuses on developing innovative solutions for detecting acute coronary syndrome (ACS), commonly known as a heart attack, at the point of need. They are a relatively new company with a focus on wearable technology and AI for cardiac monitoring.
Core Business Areas
- Diagnostic Devices: Development and commercialization of wearable ECG technology to detect and monitor cardiac activity remotely.
- AI-Powered Analytics: Utilizing artificial intelligence to analyze ECG data and provide early warnings of potential cardiac events.
Leadership and Structure
The leadership team consists of experienced professionals in the medical device and technology industries. Information on detailed organizational structure requires further research as it is not readily available.
Top Products and Market Share
Key Offerings
- Heartbeam AIMI: A 12-lead ECG system intended to monitor for heart attacks remotely by comparing two sets of ECGs. The competitors in this space include companies developing similar remote cardiac monitoring solutions, such as BioTelemetry (acquired by Philips), iRhythm Technologies, and AliveCor. Market share data for specific products is not publicly available.
Market Dynamics
Industry Overview
The cardiac monitoring market is experiencing significant growth due to an aging population, increasing prevalence of heart disease, and advancements in wearable technology and telemedicine. The market is competitive, with numerous players offering various ECG monitoring solutions.
Positioning
Heartbeam aims to differentiate itself by offering a convenient and accessible solution for early detection of cardiac events, potentially reducing the need for hospital visits and improving patient outcomes. They are a smaller player competing with established companies.
Total Addressable Market (TAM)
The global cardiac monitoring market is projected to reach billions of dollars. Heartbeam's positioning hinges on capturing a segment of the remote cardiac monitoring portion of this TAM.
Upturn SWOT Analysis
Strengths
- Innovative technology for early heart attack detection
- Potential for improved patient outcomes and reduced healthcare costs
- Focus on remote and accessible cardiac monitoring
Weaknesses
- Limited commercial history and market presence
- Dependence on regulatory approvals and clinical validation
- Strong competition from established players
Opportunities
- Expanding market for remote cardiac monitoring
- Partnerships with healthcare providers and payers
- Technological advancements in AI and wearable devices
Threats
- Regulatory hurdles and delays
- Competition from established players with greater resources
- Technological obsolescence
- Reimbursement challenges from payers.
Competitors and Market Share
Key Competitors
- IRTC
- ALVR
- PHILIPS
Competitive Landscape
Heartbeam competes in a crowded market for cardiac monitoring. Its advantages lie in its innovative technology and focus on remote solutions. Disadvantages include its limited resources and market presence compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the early stage of the company.
Future Projections: Future growth depends on successful commercialization and market acceptance of its products. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, and partnerships to expand market reach.
Summary
Heartbeam Inc. Warrant is a development-stage company with innovative technology targeting the remote cardiac monitoring market. Its success hinges on obtaining regulatory approvals, successful commercialization, and competing effectively against established players. The company's limited operating history makes it a high-risk, high-reward investment. Key areas to monitor include clinical trial results, regulatory milestones, and market adoption rates.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Press releases
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may be subject to change. Investments in early-stage companies are highly speculative and involve significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heartbeam Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-11 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 15 | Website |
Full time employees 15 | Website | ||
HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company develops three-dimensional (3D)-vector electrocardiogram (ECG) platform for heart attack detection. It is developing HeartBeam AIMI software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack; and HeartBeam AIMIGo, a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.